‘Personal lives’ of lung cancer cells help predict response to treatment
“University of Queensland researchers who mapped cancer cell “neighborhoods” in the most common type of lung cancer have found cell metabolism plays a critical role in determining how lung cancer patients will respond to immunotherapy. Their results are published in Nature Communications.”
Two Decades of Data Reveal Mortality Patterns, Disparities in Lung Cancer and Diabetes
“Mortality associated with lung cancer among patients with diabetes has continued to rise in the United States over the past two decades, with persistent racial, geographic, and sex-based disparities, according to findings from a recent study. A team of researchers from Pakistan conducted the study and published the results in The Egyptian Journal of Bronchology. The investigators cited lung cancer and diabetes as “leading causes of death worldwide” and explained that it was important to evaluate associations between the conditions as they commonly coexist in older adults and can impact prognosis and survival, despite “very limited scientific data” about the correlation.”
American Lung Association Commends Passage of Bipartisan Health Funding
“Today, the House passed, and President Trump signed into law, critical funding for the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), ensuring continued investment in lifesaving public health and research programs.”
Photon-counting CT Outperforms Conventional CT in Lung Cancer Management
“In a prospective imaging study of 200 adults with lung cancer, photon-counting CT reduced radiation exposure, had fewer adverse reactions and provided higher image quality and better detection of malignant features compared with conventional CT. Results of the study were published in Radiology.”
How tumours trick the brain into shutting down cancer-fighting cells
“Lung cancer cells in mice can connect with nearby neurons to send a ‘shutdown’ signal to the brain that suppresses tumour-killing immune cells.”
Expanding Lymph Node Assessment Could Improve Lung Cancer Staging
“Lymph node assessment should be expanded in patients undergoing surgery for non-small-cell lung cancer (NSCLC) to more accurately detect hidden systemic disease, suggests research presented at the 2026 Society of Thoracic Surgeons Annual Meeting.”
Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models
“KRAS is a common oncogene that has become targetable with new therapies primarily being allele specific. Lung cancers with G12C and G12D mutations represent two of the most common KRAS-driven subsets, with approved therapies available for G12C. However, how distinct KRAS alleles differentially shape tumor biology and immune interactions and how this influences dependence on KRAS signaling and responses to KRAS inhibition are not well understood.”
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
“PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).”
Video:
How Cancer Treatment Affects Lung Function in Survivorship
“Dr. Joshua Sabari explains how surgery, radiation and therapy may reduce lung capacity and shares steps survivors can take to protect breathing health.”
FDA Clears AI-Powered Software for Assessment of Incidental Lung Nodules on CT
“The Food and Drug Administration (FDA) has issued 510(k) clearance for the RevealAI-Lung software for the assessment of incidental lung nodules detected on CT. Validated on over 1,500 patients from a variety of cohorts, the RevealAI-Lung software enables one to click on a nodule and obtain a Malignancy Similarity Index (mSI™). Through proprietary analytics, the mSI score provides clinical insights that may facilitate earlier detection and reduce unnecessary procedures, according to RevealDx, the manufacturer of the software.”
